Antibodies News and Research

RSS

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Researchers have recovered and identified the various types of neutralizing antibodies for SARS-CoV-2 from convalescent COVID-19 patients. Of these, they identified three that are extremely potent and could be used to develop treatment therapies.

11 Oct 2020

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

The emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation D614G has raised many questions, including whether it will cause the virus to become resistant to the vaccines produced against earlier versions of the virus. A new study published in the journal npj Vaccines in October 2020 shows that this may be an unfounded fear.

11 Oct 2020

CHLA investigator receives $3.4 million research grant to study rotavirus vaccine

Rotavirus (RV) is an extremely contagious viral infection and the most common cause of diarrhea in infants and children worldwide.

9 Oct 2020

Too little sugar is the cause of perforated bones

Bone marrow cancer is currently an incurable disease that affects about 400 people in Norway every year. Professor Therese Standal at NTNU has now found an important reason for bone destruction in people with this disease.

9 Oct 2020

Antibody cocktail may offer clinical benefit in both prevention and treatment of COVID-19

In June, two studies in Science reported an antibody cocktail against SARS-CoV-2 developed from studies in humanized mice and recovering patients. The two antibody cocktail was designed to bind the virus to reduce the risk of a drug-resistant form emerging.

9 Oct 2020

Serum antibodies from SARS-CoV patients effectively neutralized SARS-CoV-2 in cultured cells

Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralized SARS-CoV-2 infection in cultured cells, according to a new study.

9 Oct 2020

Exuberant activation of immune cells in severe COVID-19 resembles lupus

In severe cases of COVID-19, Emory researchers have been observing an exuberant activation of immune cells, resembling acute flares of systemic lupus erythematosus (SLE), an autoimmune disease.

9 Oct 2020

Long-lasting antibodies detected in blood and saliva of COVID-19 patients

Two separate studies have documented the persistence of antibodies that target SARS-CoV-2 in hundreds of patients with COVID-19 at least 3 months after symptom onset.

9 Oct 2020

Transplantation of pig hearts may solve chronic shortage of donor organs

The goal of harvesting hearts from pigs to solve the chronic shortage of these donor organs appears to be in reach, according to a new scientific review by researchers at Massachusetts General Hospital (MGH).

9 Oct 2020

Higher HMBGB1 levels associated with obesity, inflammation, and cardiovascular disease in younger black adults

A "danger molecule" is higher in the blood of younger black adults than whites, females than males and increases with weight and age, researchers report in the first large, longitudinal study associating circulating HMGB1 levels with obesity, inflammation promoters and early indicators of cardiovascular risk in humans.

9 Oct 2020

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

Researchers from the Japan Advanced Institute of Science and Technology (JAIST) and Ishikawa Prefectural University, Japan, recently attempted to synthesize the ORF8 protein with the help of a chemical-inducible protein production system using tobacco BY-2 cells. This study has been published demonstrated in the preprint server, bioRxiv.

9 Oct 2020

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute as part of the NCI's new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19.

8 Oct 2020

NIH clinical trial to test a combination treatment regimen for COVID-19

A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun.

8 Oct 2020

Neutralizing responses to infection relatively common in COVID-19

A new study has shown that severe coronavirus disease 2019 (COVID-19) is associated with unique B cell receptor (BCR) signatures and multiclonal neutralizing responses against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Oct 2020

The Native Antigen Company introduces ten new SARS-CoV-2 specific antibodies

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19.

8 Oct 2020

Study estimates lower herd immunity to SARS-CoV-2 in the U.S.

A new study shows that recognizing the differences in the population composition, connectedness and distribution, as well as inter-individual differences in immunity, susceptibility and infectivity, are crucial to estimating the herd immunity attained as a result of natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) more accurately.

8 Oct 2020

Comet supercomputer performs complex calculations on receptor sequence data from human T cells

While researchers around the world race to develop an effective and safe COVID-19 vaccine, a team from the San Diego Supercomputer Center (SDSC) at UC San Diego contributed to a study led by Vanderbilt Vaccine Center of Vanderbilt University Medical Center (VUMC) on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens including the Coronavirus SARS-CoV-2.

8 Oct 2020

Experimental Chinese SARS-CoV-2 vaccine appears safe in early trials

A new study published on the preprint server medRxiv in October 2020 reports the findings of a phase I trial of an inactivated SARS-CoV-2 vaccine, demonstrating that it can elicit a potent immune response without significant adverse reactions.

7 Oct 2020

Proteolytic cleavage of nucleocapsid helps SARS-CoV-2 evade host immune responses

A team of scientists of the University of Oxford reveals that the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) undergoes autoproteolysis, and that resulting products can escape the host immune responses and facilitate viral proliferation. The study is currently available on the bioRxiv preprint server.

7 Oct 2020

Rapid, low-cost test for potential universal COVID-19 monitoring

An international team of researchers has presented a convenient, low-cost serology test to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could potentially be made available universally.

7 Oct 2020

Antibodies News and Research

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

CHLA investigator receives $3.4 million research grant to study rotavirus vaccine

Too little sugar is the cause of perforated bones

Antibody cocktail may offer clinical benefit in both prevention and treatment of COVID-19

Serum antibodies from SARS-CoV patients effectively neutralized SARS-CoV-2 in cultured cells

Exuberant activation of immune cells in severe COVID-19 resembles lupus

Long-lasting antibodies detected in blood and saliva of COVID-19 patients

Transplantation of pig hearts may solve chronic shortage of donor organs

Higher HMBGB1 levels associated with obesity, inflammation, and cardiovascular disease in younger black adults

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

NIH clinical trial to test a combination treatment regimen for COVID-19

Neutralizing responses to infection relatively common in COVID-19

The Native Antigen Company introduces ten new SARS-CoV-2 specific antibodies

Study estimates lower herd immunity to SARS-CoV-2 in the U.S.

Comet supercomputer performs complex calculations on receptor sequence data from human T cells

Experimental Chinese SARS-CoV-2 vaccine appears safe in early trials

Proteolytic cleavage of nucleocapsid helps SARS-CoV-2 evade host immune responses

Rapid, low-cost test for potential universal COVID-19 monitoring

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo